INDIA CATHETERS MARKET ANALYSIS

Market News

India Catheters Market- Key Developments

In September 2021, Medtronic, the global company in medical technology, announced it has received Conformité Européenne (CE) mark approval for its radial artery access portfolio, which includes the Rist radial access selective catheter and the Rist 079 radial access guide catheter—the first catheter specifically designed for the unique demands of accessing the neurovasculature to treat stroke, brain aneurysms, and other conditions through the radial artery versus access through the transfemoral artery.

On April 12, 2023, BACTIGUARD AB,  a global medtech company with a purpose to prevent infections announced the launch of a clinical study to gain additional clinical evidence of the efficacy of central venous catheters with Bactiguard’s infection prevention coating technology (BIP CVC) as compared with a non-coated standard catheter. The endpoints of the study will include, among others, catheter-associated bloodstream infections and thrombosis rates. The study will be performed at multiple sites in India and is under the supervision of primary investigator Dr. Yatin Metha, Medanta Hospital in New Dehli. The study has been approved by the local regulatory authorities DCGI (Drug Controller General of India).

In May 2020, Cook, a global medical device company, and Surmodics, Inc., a provider of surface modification, drug delivery, and in vitro diagnostic technologies to the healthcare industry announced an agreement in which Cook will distribute two new Surmodics products, hydrophilic percutaneous transluminal angioplasty (PTA) balloon catheters that can be used over 0.014-inch and a 0.018-inch wire guides.

In January 2022, ICU Medical Inc., a developer, manufacturer, and seller of medical products used in infusion therapy, vascular access, and vital care applications announced that it has completed its acquisition of Smiths Medical from Smiths Group plc. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical’s existing businesses, the combined companies create a leading infusion therapy company with estimated pro forma combined revenues of approximately US$ 2.5 billion.